1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;Jan-Feb;57(1):43-66. PMID:
17237035.
2. Ward EC, Van As-Brooks C. Head and neck cancer: treatment, rehabilitation, and outcomes. San Diego (CA): Plural Publishing; 2007.
3. Rudolph E, Dyckhoff G, Becher H, Dietz A, Ramroth H. Effects of tumour stage, comorbidity and therapy on survival of laryngeal cancer patients: a systematic review and a meta-analysis. Eur Arch Otorhinolaryngol. 2011 2;268(2):165-179. PMID:
20957488.
4. Zhang H, Liu M, Sun Y, Lu J. MMP-14 can serve as a prognostic marker in patients with supraglottic cancer. Eur Arch Otorhinolaryngol. 2009 9;266(9):1427-1434. PMID:
19283401.
5. Tan CT, Chu CY, Lu YC, Chang CC, Lin BR, Wu HH, et al. CXCL12/CXCR4 promotes laryngeal and hypopharyngeal squamous cell carcinoma metastasis through MMP-13-dependent invasion via the ERK1/2/AP-1 pathway. Carcinogenesis. 2008 8;29(8):1519-1527. PMID:
18487224.
6. Liu Y, Li Y, Liu Z, Zhang L, Anniko M, Duan M. Prognostic significance of matrix metalloproteinase-20 overexpression in laryngeal squamous cell carcinoma. Acta Otolaryngol. 2011 7;131(7):769-773. PMID:
21466263.
7. Lee SY, Park SY, Kim SH, Choi EC. Expression of matrix metalloproteinases and their inhibitors in squamous cell carcinoma of the tonsil and their clinical significance. Clin Exp Otorhinolaryngol. 2011 6;4(2):88-94. PMID:
21716956.
8. Vihinen P, Ala-aho R, Kahari VM. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets. 2005 5;5(3):203-220. PMID:
15892620.
9. Sarioglu S, Ozer E, Kirimca F, Sis B, Pabuccuoglu U. Matrix metalloproteinase-2 expression in laryngeal preneoplastic and neoplastic lesions. Pathol Res Pract. 2001;197(7):483-486. PMID:
11482578.
10. Bogusiewicz M, Stryjecka-Zimmer M, Szymanski M, Rechberger T, Golabek W. Activity of matrix metalloproteinases-2 and -9 in advanced laryngeal cancer. Otolaryngol Head Neck Surg. 2003 1;128(1):132-136. PMID:
12574771.
11. Peschos D, Damala C, Stefanou D, Tsanou E, Assimakopoulos D, Vougiouklakis T, et al. Expression of matrix metalloproteinase-9 (gelatinase B) in benign, premalignant and malignant laryngeal lesions. Histol Histopathol. 2006 6;21(6):603-608. PMID:
16528670.
12. Christopoulos TA, Papageorgakopoulou N, Ravazoula P, Mastronikolis NS, Papadas TA, Theocharis DA, et al. Expression of metalloproteinases and their tissue inhibitors in squamous cell laryngeal carcinoma. Oncol Rep. 2007 10;18(4):855-860. PMID:
17786346.
13. Bartlett RS, Heckman WW, Isenberg J, Thibeault SL, Dailey SH. Genetic characterization of vocal fold lesions: leukoplakia and carcinoma. Laryngoscope. 2012 2;122(2):336-342. PMID:
22252855.
14. Liu WW, Zeng ZY, Wu QL, Hou JH, Chen YY. Overexpression of MMP-2 in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Otolaryngol Head Neck Surg. 2005 3;132(3):395-400. PMID:
15746850.
15. Karahan N, Baspinar S, Yariktas M, Kapucuoglu N. Matrix Metalloproteinases (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) expressions in vocal fold polyps. J Voice. 2009 1;23(1):29-33. PMID:
17624726.
16. Katayama A, Bandoh N, Kishibe K, Takahara M, Ogino T, Nonaka S, et al. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res. 2004 1;10(2):634-640. PMID:
14760086.
17. Gorogh T, Beier UH, Baumken J, Meyer JE, Hoffmann M, Gottschlich S, et al. Metalloproteinases and their inhibitors: influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas. Head Neck. 2006 1;28(1):31-39. PMID:
16265652.
18. Whittaker M, Ayscough A. Matrix metalloproteinases and their inhibitors: current status and future challenges. Celltransmissions. 2001 2;17(1):3-14.
19. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000 3;18(5):1135-1149. PMID:
10694567.
20. Danilewicz M, Sikorska B, Wagrowska-Danilewicz M. Prognostic significance of the immunoexpression of matrix metalloproteinase MMP2 and its inhibitor TIMP2 in laryngeal cancer. Med Sci Monit. 2003 3;9(3):MT42-MT47. PMID:
12640351.
21. Jodele S, Blavier L, Yoon JM, DeClerck YA. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev. 2006 3;25(1):35-43. PMID:
16680570.
22. Wittekindt C, Jovanovic N, Guntinas-Lichius O. Expression of matrix metalloproteinase-9 (MMP-9) and blood vessel density in laryngeal squamous cell carcinomas. Acta Otolaryngol. 2011 1;131(1):101-106. PMID:
20873997.
23. Hanata K, Yamaguchi N, Yoshikawa K, Mezaki Y, Miura M, Suzuki S, et al. Soluble EMMPRIN (extra-cellular matrix metalloproteinase inducer) stimulates the migration of HEp-2 human laryngeal carcinoma cells, accompanied by increased MMP-2 production in fibroblasts. Arch Histol Cytol. 2007 12;70(5):267-277. PMID:
18431027.
24. Xie M, Sun Y, Li Y. Expression of matrix metalloproteinases in supraglottic carcinoma and its clinical implication for estimating lymph node metastases. Laryngoscope. 2004 12;114(12):2243-2248. PMID:
15564854.
25. Roepman P, Kemmeren P, Wessels LF, Slootweg PJ, Holstege FC. Multiple robust signatures for detecting lymph node metastasis in head and neck cancer. Cancer Res. 2006 2;66(4):2361-2366. PMID:
16489042.
26. Yuce I, Bayram A, Cagli S, Canoz O, Bayram S, Guney E. The role of CD44 and matrix metalloproteinase-9 expression in predicting neck metastasis of supraglottic laryngeal carcinoma. Am J Otolaryngol. 2011;Mar-Apr;32(2):141-146. PMID:
20434807.
27. Mallis A, Teymoortash A, Mastronikolis NS, Werner JA, Papadas TA. MMP-2 expression in 102 patients with glottic laryngeal cancer. Eur Arch Otorhinolaryngol. 2012 2;269(2):639-642. PMID:
21667117.
28. Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T. Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. Clin Cancer Res. 2004 5;10(9):3110-3116. PMID:
15131051.
29. Kosunen A, Pirinen R, Ropponen K, Pukkila M, Kellokoski J, Virtaniemi J, et al. CD44 expression and its relationship with MMP-9, clinicopathological factors and survival in oral squamous cell carcinoma. Oral Oncol. 2007 1;43(1):51-59. PMID:
16798062.
30. Sun Y, Liu M, Yang B, Li B, Lu J. Role of siRNA silencing of MMP-2 gene on invasion and growth of laryngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2008 11;265(11):1385-1391. PMID:
18437407.